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Editorial Comment
Long-Term Survival After
Pharmacologic and Mechanical
Recanalization in Acute
Myocardial Infarction*
HILTRUD S. MUELLER, MD, FACC
Bronx, New York
Previous studies . Thrombolysis has become an integral
part of the treatment of acute myocardial infarction . The
contention that early percutaneous transluminal coronary
angioplasty will improve hospital and long-term outcome
was intensively tested and remains under investigation .
Three trials (1-3) recently demonstrated that immediate
coronary angioplasty after thrombolysis with recombinant
tissue-type plasminogen activator (rt-PA) is not advisable,
and that left ventricular function in general is not compro-
mised by delayed angioplasty . The second Thrombolysis in
Myocardial Infarction study (TIMI-IIB) (4) showed that a
conservative strategy after thrombolysis with "watchful
waiting" and prompt attention to recurrent ischemic events
had results as favorable as those of thrombolysis and de-
ferred angioplasty. Subgroup analysis is being conducted to
identify high risk patients . Several investigators (5-10) dem-
onstrated that patients at high risk after acute myocardial
infarction, such as those in cardiogenic shock or with low
ejection fraction, benefit from immediate mechanical reca-
nalization . At present, the impact of early "complete coro-
nary recanalization" on short- and long-term outcome in the
general population of patients with infarction is under debate
and investigation . Stack et al . (8), using intravenous strep-
tokinase and immediate coronary angioplasty, accomplished
a >90% patency rate of the infarct artery in the acute phase
and before hospital discharge . Despite inclusion of 13% of
patients in cardiogenic shock, the hospital and 1 year post-
discharge mortality rate was low (11% and .7%, respec-
tively) and was associated with a low reinfarction rate .
However, there was no control group . Other studies (11-13)
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emphasized the benefit of an open infarct artery to long-term
outcome .
The present study . In this issue of the Journal, Erbel et al .
(14) report a study of patients with acute myocardial infarc-
tion, comparing the efficacy of thrombolysis and immediate
angioplasty with that of thrombolysis alone . They conclude
that survival over a 3 year period did not significantly differ
between the two treatment groups .
Long-term outcome depends on events during the acute
phase of myocardial infarction . Several points emphasizing
the fast evolution of recanalization therapy should be con-
sidered to put the results of Erbel et al . (14) in perspective .
The study was performed from 1983 to 1985, at a time when
thrombolysis was still evolving . In the streptokinase treat-
ment group of their study, the cardiac mortality rate was
high (14 .5%). Eliminating the six patients in cardiogenic
shock and the four related deaths, the hospital mortality rate
remains 11% in a patient group with a baseline average
ejection fraction of 55% and an early recanalization rate of
the infarct artery of 84% . This mortality rate is higher than
that of other studies using intracoronary (15,16) or intracor-
onary and intravenous streptokinase (17), and higher (18)
than or comparable (19) with that of studies using intrave-
nous streptokinase alone . The most important factor for this
high hospital mortality rate is probably the lack of aggressive
management of recurrent ischemic events . Sixteen patients
experienced reinfarction or reocclusion during the hospital
phase . Seven of the 15 cardiac deaths were caused by
reinfarction . The rate of procedures was low-only three
patients underwent coronary angioplasty ; coronary bypass
grafting, performed in seven patients, was mainly related to
high risk coronary anatomy .
Considering the results of the streptokinase/angioplasty
group in the study of Erbel et al . (14), one should appreciate
that the technique of angioplasty was less advanced than it is
today . Fifty-five percent of the 103 patients underwent
successful angioplasty, 16% had a totally occluded infarct
artery and the majority of the remaining patients were left
with a significantly stenosed vessel . Importantly, recurrent
ischemic events were not aggressively treated . In light of the
reocclusion and reinfarction rate during the hospital phase,
probably <50% of the patients remained with an effectively
opened infarct artery at hospital discharge .
Comparison of the results of the two treatment groups
during the hospital phase reveals a trend toward more
frequent ischemic events and deaths in the streptokinase
group. Of note, the difference in mortality might have been
greater if the patients in cardiogenic shock had been evenly
distributed . There were 6 patients in shock (4 who died) in
the streptokinase group compared with 14 patients in shock
(5 who died) in the streptokinase/angioplasty group ; this
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Table 1 .
Hospital and 1 Year Mortality in Three
Thrombolysis Trials
GISSI = Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto
Miocardico ; rt-PA = recombinant tissue-type plasminogen activator ; TIMI =
Thrombolysis in Myocardial Infarction study ; t = difference .
discrepancy probably falsely lowered the mortality in the
streptokinase group .
Follow-up results .
The follow-up data of the study of
Erbel et al
. (14) should be interpreted in the light of the
aforementioned comments . Much has been learned about
the short-term results of various forms of coronary recana-
lization, but less is known about the "natural history" of
patients after coronary recanalization
. The Gruppo Italiano
per to Studio della Streptochinasi nell'Infarto Miocardico
(GISSI) study (
0, 1) first convincingly demonstrated that
the beneficial effects of thrombolysis observed during hos-
pitalization are maintained during the subsequent year. It
also emphasized that the pattern of response was established
during the hospital phase without additional benefit (or loss
of benefit) after discharge . The follow-up phase represents a
"holding pattern" expressed by the parallel course of the
survival lines of the two treatment groups
. This pattern is
observed whether thrombolytic agent and placebo (17, 0, 1)
or two thrombolytic agents (1 ) are compared (Table 1) .
Post-discharge 1 year mortality rates did not significantly
differ between the two treatment groups in the various
studies . The follow-up data of Erbel et al . (14) are of interest
because one of the treatment arms included coronary angio-
plasty. The results are similar to those just described . The
pattern of response was established during the hospital
phase and the survival lines remained parallel during the 3
year follow-up period
. The contention that the post-
discharge mortality rate would be lower in the streptokinase/
angioplasty arm than in the streptokinase arm did not hold .
Post-discharge 1 year mortality rates were 6 .6% (streptoki-
nase/angioplasty) and 4 .6% (streptokinase arm), and 4.4%
and 4.6% if cardiac mortality only is considered (note : only
two deaths in each group were noncardiac ; the remaining
were related to myocardial infarction or treatment, as appar-
ent in Table 4 of Erbel et al .) .
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Implications . Erbel et al. (14) should be commended for
their study . They contributed early
to the introduction of
two modalities of coronary recanalization to the treatment of
acute myocardial infarction
. However, because of the fast
evolution of recanalization therapy and related methodol-
ogy, the study cannot answer the question whether early
coronary angioplasty in addition to thrombolysis improves
hospital and long-term outcome . The results of ongoing trials
have to be awaited to establish the role of early "complete
coronary recanalization" in acute myocardial infarction
.
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